These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 23139179)

  • 1. Antigen generation and display in therapeutic antibody drug discovery -- a neglected but critical player.
    Ebersbach H; Geisse S
    Biotechnol J; 2012 Dec; 7(12):1433-43. PubMed ID: 23139179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolation of functional single domain antibody by whole cell immunization: implications for cancer treatment.
    Baral TN; Murad Y; Nguyen TD; Iqbal U; Zhang J
    J Immunol Methods; 2011 Aug; 371(1-2):70-80. PubMed ID: 21741385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing properties of antireceptor antibodies using kinetic computational models and experiments.
    Harms BD; Kearns JD; Su SV; Kohli N; Nielsen UB; Schoeberl B
    Methods Enzymol; 2012; 502():67-87. PubMed ID: 22208982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein antigen expression in Escherichia coli for antibody production.
    Rancour DM; Backues SK; Bednarek SY
    Methods Mol Biol; 2010; 657():3-20. PubMed ID: 20602203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The rapid discovery of engineered antibodies.
    Wang M; He M
    IDrugs; 2007 Aug; 10(8):562-5. PubMed ID: 17665332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arrayed antibody library technology for therapeutic biologic discovery.
    Bentley CA; Bazirgan OA; Graziano JJ; Holmes EM; Smider VV
    Methods; 2013 Mar; 60(1):91-8. PubMed ID: 23485577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Designing and optimizing library selection strategies for generating high-affinity antibodies.
    Hoogenboom HR
    Trends Biotechnol; 1997 Feb; 15(2):62-70. PubMed ID: 9081300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumoral effect of active immunotherapy in C57BL/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants.
    Morera Y; Bequet-Romero M; Ayala M; Lamdán H; Agger EM; Andersen P; Gavilondo JV
    Angiogenesis; 2008; 11(4):381-93. PubMed ID: 19034678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineered antibodies take center stage.
    Huston JS; George AJ
    Hum Antibodies; 2001; 10(3-4):127-42. PubMed ID: 11847424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting.
    Gu J; Ghayur T
    Methods Enzymol; 2012; 502():25-41. PubMed ID: 22208980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant antibodies with MHC-restricted, peptide-specific, T-cell receptor-like specificity: new tools to study antigen presentation and TCR-peptide-MHC interactions.
    Cohen CJ; Denkberg G; Lev A; Epel M; Reiter Y
    J Mol Recognit; 2003; 16(5):324-32. PubMed ID: 14523945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody engineering and modification technologies.
    Filpula D
    Biomol Eng; 2007 Jun; 24(2):201-15. PubMed ID: 17466589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The biotechnology and applications of antibody engineering.
    Rapley R
    Mol Biotechnol; 1995 Apr; 3(2):139-54. PubMed ID: 7620975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction of cell surface-engineered yeasts displaying antigen to detect antibodies by immunofluorescence and yeast-ELISA.
    Tang YQ; Han SY; Zheng H; Wu L; Ueda M; Wang XN; Lin Y
    Appl Microbiol Biotechnol; 2008 Jul; 79(6):1019-26. PubMed ID: 18542951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibodies and genetically engineered related molecules: production and purification.
    Roque AC; Lowe CR; Taipa MA
    Biotechnol Prog; 2004; 20(3):639-54. PubMed ID: 15176864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bacterial display in combinatorial protein engineering.
    Löfblom J
    Biotechnol J; 2011 Sep; 6(9):1115-29. PubMed ID: 21786423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibodies as targeting and therapeutic agents: prospects for liver transplantation, hepatitis and hepatocellular carcinoma.
    Luk JM; Wong KF
    Clin Exp Pharmacol Physiol; 2006; 33(5-6):482-8. PubMed ID: 16700883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant antibody libraries and selection technologies.
    Zhou H; Zhang YL; Lu G; Ji H; Rodi CP
    N Biotechnol; 2011 Sep; 28(5):448-52. PubMed ID: 21477669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates.
    Vincent KJ; Zurini M
    Biotechnol J; 2012 Dec; 7(12):1444-50. PubMed ID: 23125076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic antibody production technologies: molecules, applications, expression and purification.
    Humphreys DP; Glover DJ
    Curr Opin Drug Discov Devel; 2001 Mar; 4(2):172-85. PubMed ID: 11378956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.